Annual report for Bafna Pharmaceuticals Ltd. for FY-2020
25-06-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Board Meeting For Audited Result And Other Business Matters (General)
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/06/2020 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 25th June 2020 to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2020 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.13-06-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2020
Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2020.28-05-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended March 31, 2020
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here14-05-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer13-05-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate For The Half Year Ended 31St March 2020
Compliance Certificate that all activities in relation to share transfer facility are maintained by Registrar to an issue and share transfer agent registered with the Board under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2020 is hereby enclosed for your reference.07-05-2020
Bafna Pharmaceuticals Ltd - 532989 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Pursuant to the successful implementation of approved Resolution Plan, the Implementation and Monitoring Committee at their meeting held on 02nd March 2020 handed over the Corporate Debtor to the successful Resolution Applicant Mr. Mahaveer Chand Bafna. The Closure Report has been filed with NCLT,Chennai by the Supervisor of Implementation and Monitoring Committee.16-03-2020
Bafna Pharmaceuticals Ltd - 532989 - Annoucement Under Regulation 30 Of LODR
We would like to inform you that the Board at its meeting held on today approved: 1. The un-audited financial results for the Third Quarter ending 31st December 2019. Please find attached the un-audited financial results for Third Quarter ending 31st December 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. Re-appointment A.K.Jain & Associates, Company Secretaries, Chennai as Secretarial Auditor for the financial year 2019-20. 3. Increase of remuneration of Mr. Mahaveer Chand Bafna, Managing Director 4. Increase of remuneration of Mr. Paras Bafna, Whole-Time Director 5. Re-appointment of Mrs. Sabitha (Whole Time Director-Women Director), w.e.f 27th March 2020 for a period of three years and Increase of remuneration. 6. Increase of Remuneration of CFO. 7. Increase of Remuneration of Company Secretary. 8. Write off of investment in the Subsidiary Company Bafna Lifestyles Remedies Limited13-02-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Finacial Result For 31St Dec 2019
1. The un-audited financial results for the Third Quarter ending 31st December 2019. Please find attached the un-audited financial results for Third Quarter ending 31st December 2019 along with the Limited Review Report obtained from the statutory auditor of the Company13-02-2020
BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome Of Board Meeting Held On 13Th Feb 2020
1. The un-audited financial results for the Third Quarter ending 31st December 2019. Please find attached the un-audited financial results for Third Quarter ending 31st December 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. Re-appointment A.K.Jain & Associates, Company Secretaries, Chennai as Secretarial Auditor for the financial year 2019-20. 3. Increase of remuneration of Mr. Mahaveer Chand Bafna, Managing Director 4. Increase of remuneration of Mr. Paras Bafna, Whole-Time Director 5. Re-appointment of Mrs. Sabitha (Whole Time Director-Women Director), w.e.f 27th March 2020 for a period of three years and Increase of remuneration. 6. Increase of Remuneration of CFO. 7. Increase of Remuneration of Company Secretary. 8. Write off of investment in the Subsidiary Company Bafna Lifestyles Remedies Limited.13-02-2020